Skip to main content

Table 3 Changes in serum adipokines during the study

From: Increased high molecular weight adiponectin and lean mass during tocilizumab treatment in patients with rheumatoid arthritis: a 12-month multicentre study

 

M0 (N = 107)

M1 (N = 106)

M3 (N = 104)

M6 (N = 97)

M12 (N = 77)

P*, M0 vs M6 (N = 97)

P*, M0 vs M12 (N = 77)

P#

Total adiponectin (μg/mL)

14.54 ± 8.1

15.5 ± 8.7

15.7 ± 9.9

14.6 ± 7.5

14.2 ± 7.6

0.055

0.25

0.3

Total adiponectin (μg/mL), TCZ alone

15.18 ± 7.8

14.75 ± 7.9

14.76 ± 6.6

15.03 ± 7.5

14.23 ± 6.6

0.34

0.8

0.31

Total Adiponectin (μg/mL), TCZ and csDMARDs

14.40 ± 8.3

15.82 ± 9.1

16.04 ± 11.0

14.47 ± 7.6

14.14 ± 8.2

0.1

0.24

0.019

HMW adiponectin (μg/mL)

7.3 ± 5.4

8.3 ± 6.6

8 ± 6.4

7.5 ± 5,4

6.8 ± 4.6

0.011

0.057

0.01

HMW adiponectin (μg/mL), TCZ alone

7.32 ± 4.50

7.87 ± 5.40

7.94 ± 5.22

7.97 ± 5.21

7.03 ± 4.72

0.052

0.046

0.09

HMW adiponectin (μg/mL), TCZ and csDMARDs

7.07 ± 5.28

8.42 ± 7.08

8.06 ± 6.84

7.32 ± 5.47

6.73 ± 4.66

0.045

0.3

0.045

Leptin (ng/mL)

32.64 ± 26.9

32.45 ± 25.4

31.7 ± 23.6

32.6 ± 27.3

32.8 ± 27.5

0.059

0.17

0.22

Leptin/fat mass

1.08 ± 0.7

ND

ND

1.1 ± 0.8

1.2 ± 1.4

0.049

0.2

0.14

Resistin (ng/mL)

10.5 ± 4.9

11 ± 4.9

10.9 ± 4.6

10.8 ± 4,9

10.9 ± 5.3

0.53

0.16

0.13

Ghrelin (pg/mL)

2121.9 ± 1309.4

2031.5 ± 1266

2072.9 ± 1299

2074.8 ± 1278.4

2035 ± 1304.3

0.78

0.19

0.28

  1. Results are given as mean ± SD
  2. M month, TCZ tocilizumab, HMW high molecular weight, ND not determined
  3. *Paired Student’s t test
  4. #Sensitivity analysis